Innovive Pharmaceuticals Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: New York NY United States (2004)
Status: Acquired by CytRx (2008)

Organization Overview

First Clinical Trial
2005
NCT00255333
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (2)

Key: Innovive Pharmaceuticals (0) Acquired (2)

angiotensin ii (5 trials)

vasopressin (vasostrict) (1 trial)

Drugs in Phase 3 Trials (8)

Key: Innovive Pharmaceuticals (0) Acquired (8)

abetimus (3 trials)

cilastatin (primaxin) (3 trials)

colistin (1 trial)

etx2514 (5 trials)

imipenem (primaxin) (3 trials)

ljpc-501 (4 trials)

phosphate-buffered saline (1 trial)

sulbactam (unasyn) (5 trials)

Drugs in Phase 2 Trials (4)

Key: Innovive Pharmaceuticals (0) Acquired (4)

etoposide (vepesid) (1 trial)

gcs-100 (8 trials)

ly2787106 (2 trials)

urea (2 trials)

Drugs in Phase 1 Trials (9)

Key: Innovive Pharmaceuticals (4) Acquired (5)

bortezomib (velcade) (1 trial)

cefpodoxime (vantin) (1 trial)

etx0282 (1 trial)

incomplete freund's adjuvant (1 trial)

inno-105 (1 trial)

moxifloxacin (avelox) (1 trial)

sargramostim (leukine) (2 trials)

wt-1 (2 trials)

zoliflodacin (1 trial)

Drugs in Other Trials (1)

montanide isa 720 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Lung Neoplasms (Phase 1)

Mesothelioma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Preleukemia (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 34
  • # of Trial APIs: 24